Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 11.37% is 46% below its 2-year average of 21.09%, near the low end of its 2-year range (5.73%–69.40%).
As of the fiscal period ended Tuesday, June 30, 2026. 24.10% above its 12-month average of 9.16%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 11.37%.
DEBT TO ASSETS RATIO
11.37%
DEBT TO ASSETS RATIO AVG TTM
9.16%
DEBT TO ASSETS RATIO AVG 3Y
N/A
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+24.10%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 597 covered companies
CURRENT VS SECTOR MEDIAN
+11265.72%
vs the sector median at left
Maze Therapeutics, Inc.
Market Cap
$1.45B
Debt to Assets Ratio
11.37%
TTM Avg
9.16%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.46B
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.49B
Debt to Assets Ratio
0.25%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.39B
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | $1.45B | 11.37% | 9.16% | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 0.02% | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.44B | N/A | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.48B | 0.00% | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 0.85% | N/A | N/A | N/A |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.49B | 0.25% | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.50B | 0.21% | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | 0.03% | N/A | N/A | N/A |
| Innoviva, Inc. (INVA)vs › | $1.53B | 0.16% | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.36B | 0.01% | N/A | N/A | N/A |
Debt/Assets
11.4%
Debt/Equity
0.13
Current Ratio
18.31
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 11.37% |
| 2026-03-31 | 14.59% |
| 2025-12-31 | 5.87% |
| 2025-09-30 | 5.73% |
| 2025-06-30 | 8.24% |
| 2025-03-31 | 7.76% |
| 2024-12-31 | 11.07% |
| 2024-09-30 | 41.13% |
| 2024-06-30 | 35.79% |
| 2023-12-31 | 69.40% |
